The C-terminal protoxin region of *Bacillus thuringiensis* Cry1Ab toxin has a functional role in binding to GPI-anchored receptors in the insect midgut

Received for publication, August 1, 2018, and in revised form, October 15, 2018. Published, Papers in Press, November 1, 2018, DOI 10.1074/jbc.RA118.005101

Arlen Peña-Cardeña, Ricardo Grande, Jorge Sánchez, Bruce E. Tabashnik, Alejandra Bravo, Mario Soberón, and Isabel Gómez

From the †Departamento de Microbiología Molecular and ‡Unidad de Secuenciación Masiva y Bioinformática, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Avenida Universidad 2001, Colonia Chamilpa, Cuernavaca, Morelos 62210, México and the §Department of Entomology, University of Arizona, Tucson, Arizona 85721

Edited by Chris Whitfield

*Bacillus thuringiensis* Cry toxins are used worldwide for controlling insects. Cry1Ab is produced as a 130-kDa protoxin that is activated by proteolytic removal of an inert 500 amino-acid-long C-terminal region, enabling the activated toxin to bind to insect midgut receptor proteins, leading to its membrane insertion and pore formation. It has been proposed that the C-terminal region is only involved in toxin crystallization, but its role in receptor binding is undefined. Here we show that the C-terminal region of Cry1Ab protoxin provides additional binding sites for alkaline phosphatase (ALP) and aminopeptidase N (APN) insect receptors. ELISA, ligand blot, surface plasmon resonance, and pulldown assays revealed that the Cry1Ab C-terminal region binds to both ALP and APN but not to cadherin. Thus, the C-terminal region provided a higher binding affinity of the protoxin to the gut membrane that correlated with higher toxicity of protoxin than activated toxin. Moreover, Cry1Ab domain II loop 2 or 3 mutations reduced binding of the protoxin to cadherin but not to ALP or APN, supporting the idea that protoxins have additional binding sites. These results imply that two different regions mediate the binding of Cry1Ab protoxin to membrane receptors, one located in domain II–III of the toxin and another in its C-terminal region, suggesting an active role of the C-terminal protoxin fragment in the mode of action of Cry toxins. These results suggest that future manipulations of the C-terminal protoxin region could alter the specificity and increase the toxicity of *B. thuringiensis* proteins.

Insecticidal proteins from the soil bacterium *Bacillus thuringiensis* (Bt) are used extensively in transgenic plants and sprays to control insect pests (1, 2). These Bt proteins are especially valuable because they kill some of the world’s most harmful pests but are not toxic to people and most other organisms (3–5). Cultivation of crops genetically engineered to produce Bt proteins increased to over 100 million hectares in 2017 (1). Although Bt proteins have provided substantial economic and environmental benefits (1, 2, 6–11), rapid evolution of pest resistance is reducing these advantages (12, 13).

A better understanding of the mode of action of Bt proteins is needed to improve and sustain their efficacy. Many studies have investigated the mode of action of the crystalline (Cry) Bt proteins in the Cry1A family, which kill caterpillar pests and are produced by widely adopted transgenic Bt corn, cotton, and soybeans (1, 2, 14, 15). To exert toxicity, Cry1A proteins bind to insect midgut receptors, such as glycosylphosphatidylinositol-anchored proteins like aminopeptidase N (APN), alkaline phosphatase (ALP) or to a transmembrane cadherin (CAD) to exert toxicity (14, 16). In particular, loops 2 and 3 of domain II of Cry1A toxins are important for binding to midgut receptors (14, 16). The different models of the Bt mode of action described so far include conversion of the full-length Cry1A protoxins by insect midgut proteases to yield activated toxins that bind to insect midgut receptors (14–17). This activation entails removal of ~40 amino acids from the N terminus and more than 500 amino acids from the C terminus, converting the protoxins (~130 kDa) into activated toxins (~65 kDa) (14, 15).

The "classical model" of the Bt mode of action asserts that protoxins must be converted to activated toxins before receptor binding, toxin oligomerization, and pore formation. Thus, this model does not include any role the C-terminal fragment of the protoxin may have in the mode of action of Cry toxins (14, 15). Contrary to this paradigm, bioassays performed against at least 10 resistant strains selected with activated Cry1Ac toxin of four major lepidopteran pests showed that the Cry1Ac protoxin was still able to kill populations resistant to activated toxin, showing 5- to 50-fold higher potency than the activated toxin (18–20). These results with whole insects imply that the intact protoxin or some part of the protoxin other than the activated toxin contributes to toxicity.

In vitro experiments with different fragments of CAD receptor from *Pectinophora gossypii* and *Manduca sexta* demonstrated that both the protoxin and activated toxin forms of Cry1Ac or Cry1Ab bind to the CAD receptor, specifically to...
C-terminal region of Cry1Ab protoxin binds to APN and ALP

CAD repeats 8–11 (CR8–11) from *P. gossypiella* CAD and to CR7–12 from *M. sexta* (21, 22). Furthermore, both forms promoted different post-binding events in the toxic pathway; two different pathways of oligomerization and pore formation have been described that are based on the interaction of protoxin or the activated toxin with the CAD receptor (18, 21). One oligomer is formed by protease activation of the protoxin after binding to CAD, and a different oligomer is formed by the activated toxin after binding to CAD (21). These oligomers have different sensitivities to temperature and differ in their open probability and conductance (21). In bioassays performed in the cell line CF203 from *Choristoneura fumiferana* showed that both the intact Cry1Ac protoxin without activation and the activated Cry1Ac toxin were toxic to these cells, but the cytological damage to treated cells differed between them (23). The aforementioned *in vitro* experiments performed in the cell line directly tested the effects of intact protoxins because they excluded the proteolytic activation that occurs in insect midguts.

The C-terminal protoxin region of Cry1A toxins has been proposed to be an inert region of the protein that is only involved in crystallization of Cry proteins during the sporulation phase of Bt, and no other role in the mechanism of action of Cry proteins has been attributed to this region (15, 24). However, this C-terminal protoxin region, which is removed during activation, is organized into distinct structural domains (24), where domains V and VII resemble carbohydrate-binding modules and are structurally similar to domains II and III of the activated toxin (24), which mediate binding to midgut receptors (15).

The objective of this work was to determine whether the C-terminal region of the protein has a role in Cry toxicity. Our hypothesis was that the C-terminal portion of the protoxin has an active role in Cry toxicity by binding to insect midgut receptors. Here we report the first tests of that hypothesis, performed with different binding assays. Also, we analyzed different single-point Cry1Ab mutants with alterations in domain II that were previously reported to be affected in binding interaction with Cry receptors but were analyzed only as activated toxins (25–31). Overall, our results indicate that the C-terminal fragment of Cry1Ab protoxin is directly involved in the protoxin mode of action by binding to Cry toxin receptors. This region of protoxin contributes to toxicity with additional binding sites to ALP and APN, whereas domain II contributes to CAD binding.

Results

**Binding of the C-terminal fragment of Cry1Ab protoxin to *M. sexta* brush border membrane vesicles and to Cry1Ab receptors**

To determine whether the C-terminal portion of Cry1Ab protoxin binds to insect midgut receptors, the C-terminal region of Cry1Ab protoxin was cloned, expressed in *Escherichia coli* cells, and purified by affinity chromatography (Fig. 1). The Cry1Ab protoxin was obtained from solubilized purified crystal inclusions, and the Cry1Ab activated toxin was purified by anion exchange chromatography after protoxin activation with trypsin (Fig. S1). Fig. S2 shows the Western blot analysis of these samples using anti-Cry1Ab toxin or anti-C-terminal antibodies, showing that anti-Cry1Ab toxin antibody cross-reacts with activated toxin and protoxin, but not with the C-terminal fragment and the anti-C-terminal antibody recognized both protoxin and the C-terminal fragment, and did not recognize the activated toxin.

The toxicity of these samples was tested against *M. sexta* neonate larvae. The C-terminal fragment was not toxic to the larvae; no toxicity was observed with 5 μg/cm² of this protein. However, the protoxin showed an LC₅₀ value of 3.4 ng/cm² (95% fiducial limits, 2.5–4.3), in contrast to the activated toxin, which showed an LC₅₀ value of 10.3 ng/cm² (95% fiducial limits, 7.8–13), showing that the protoxin was 3-fold more toxic than the activated toxin.

The binding analysis of purified protoxin, activated toxin, or C-terminal fragment to BBMVs from *M. sexta* showed that the C-terminal fragment also interacts with BBMVs with a high apparent binding affinity (*Kₐ* = 25 nM), similar to the apparent binding affinity of the protoxin (*Kₐ* = 16 nM) and the activated toxin (*Kₐ* = 18 nM) (Fig. 2). To determine whether the C-terminal fragment was able to bind to Cry protein receptors such as CAD, APN, or ALP, we performed ELISA binding assays using purified ALP, APN, and CAD (CR7–12 fragment) expressed in *E. coli* cells (Fig. S3). We used the CAD fragment CR7–12 (residues M810-A1485 of *M. sexta* CAD) because this fragment contains all three epitopes of CAD protein involved in Cry1Ab binding (32–34). Our data show that the C-terminal fragment bound to ALP and APN with high affinity (*Kₐ* values of 55 ± 9 nM and 24 ± 3 nM, respectively) (Fig. 3A) but showed extremely low absorbance values at 490 nm in the ELISA binding assay in the interaction with CAD (CR7–12). These data were confirmed by kinetic binding studies performed with the immobilized C-terminal fragment in surface plasmon resonance (SPR) assays, which showed that the C-terminal region was able to bind to APN and ALP with high affinity (*Kₐ* values of 185 ± 3 nM and 88 ± 5 nM, respectively) but not to CAD (CR7–12) (Fig. 3B). We also performed ligand blot assays of the protoxin, activated toxin, and C-terminal fragment to different concentrations of each receptor molecule (CR7–12, ALP, and APN).
These data confirmed that the C-terminal fragment did not bind to CAD (CR7–12) but was able to bind to ALP and APN (Fig. 4).

Finally, to demonstrate that the C-terminal fragment of Cry1Ab was able to interact with APN and ALP but not with the complete CAD receptor that is present in the insect BBMVs, pulldown assays with BBMV proteins from *M. sexta* were performed. Fig. 5 shows that CAD was pulled down by the Cry1Ab protoxin and by the activated toxin but not by the C-terminal fragment, supporting that the C-terminal region of Cry1Ab was unable to bind to the CAD receptor. As expected, we found that APN was pulled down by the Cry1Ab protoxin, activated toxin, and C-terminal fragment (Fig. 5). However, ALP was pulled down strongly by the C-terminal fragment but not by protoxin and only weakly by activated toxin (Fig. 5).

**Binding of WT and mutant Cry1Ab protoxins and activated toxins to recombinant CAD, ALP, and APN receptors**

We compared the binding interaction of Cry1Ab protoxin and activated toxin with the recombinant purified receptors. Fig. 6A shows the results of ELISA binding assays of WT Cry1Ab protoxin and activated toxin to CAD (CR12), where the apparent binding affinity was 2.4-fold higher for the activated toxin than the protoxin (Fig. 6A and Table 1). Conversely, for APN and ALP receptors, the apparent binding affinity was higher for protoxin than for activated toxin (11- and 3.7-fold higher for protoxin binding to ALP and APN, respectively, than the activated toxin) (Fig. 6, B and C, and Table 1).

We worked with some Cry1Ab mutant proteins (Cry1Ab-RR368–369AA, Cry1Ab-F371A, and Cry1Ab-G439D) that are located in domain II of Cry1Ab toxin and were characterized previously, showing reduced binding to BBMVs and lower toxicity to *M. sexta* (25–31). It is important to mention that the binding data of these mutants to BBMVs or to purified receptors that were reported before were performed only with activated toxin. Here we compared the binding of the protoxin and the activated toxin from these mutants to purified APN, ALP, and CAD (CR12) receptors. Cry1Ab-RR368–369AA and Cry1Ab-F371A have mutations in domain II loop 2 (16, 25–28).

Previous work showed that the activated Cry1Ab-RR368–369AA mutant toxin had reduced binding to APN in SPR
assays, and the activated form of Cry1Ab-F371A mutant toxin showed reduced binding to *M. sexta* BBMVs (16, 25–28). Previous work showed that the activated form of Cry1Ab-G439D mutant toxin with a mutation in domain II loop 3 showed reduced binding with the CAD (CR12) fragment (29–31). Fig. S1 shows the purified protoxin and the activated toxin molecules from the different mutant proteins. We used the CAD fragment CR12 (residues G1370–A1485 of *M. sexta* CAD) because it is an important Cry1Ab-binding region of CAD (33–35), and the binding phenotype of the Cry1Ab mutants has been reported previously with the CAD binding site CR12 (30). For the three Cry1Ab mutants, the apparent binding affinity of protoxins and activated toxins to CAD was reduced more than 11-fold relative to the WT Cry1Ab, and a final $K_d$ value could not be determined (Table 1 and Fig. 6A). These results imply that both of these domain II exposed loops participate in the binding of protoxin and activated toxin to CAD. In contrast, the apparent binding affinity to ALP and APN was similar for the protoxins of these three mutants relative to the WT Cry1Ab protoxin (Table 1 and Fig. 6, B and C). The binding analysis of the activated toxin form of these mutants showed that Cry1Ab-F371A did not reduce binding to ALP or APN; Cry1Ab-RR368–369AA reduced binding 1.3-fold to ALP and 1.9-fold to APN, and Cry1Ab-G439D reduced binding 2.7-fold to ALP and 2.9-fold to APN (Table 1, Fig. 6, B and C). These results suggest that loops 2 and 3 of domain II, particularly loop 3, contribute to binding of Cry1Ab activated toxin to ALP and APN. The new data showed that these mutations were not affected in the binding interaction of their protoxin molecules to ALP and APN, supporting that additional regions present in the protoxin are involved in ALP and APN binding.

**Discussion**

We discovered that ALP and APN from *M. sexta* interact with high affinity with the C-terminal region of Cry1Ab protoxin (Figs. 3–5). The C-terminal fragment was produced in
shows a model of the mechanism of action of affinity binding sites of protoxins to the abundant glycosylphosphatidylinositol-anchored proteins could provide means for the binding of protoxin to brush border membranes before its activation. Interaction of protoxin with CAD by binding affinity of Cry1Ab protoxin to both receptors was higher than activated toxin (Table 1), indicating that C-terminal fragment has additional binding sites for these receptors. These results do not support the notion that the C-terminal region of protoxins is solely involved in crystal formation and has no role in the toxicity of Cry proteins (14, 15, 35, 37). Conversely, they are consistent with the proposition that the C-terminal regions of protoxins contribute to the binding and toxicity of Cry proteins (18, 21). The idea that protoxins participate in toxicity by binding to Cry toxin receptors is also supported by the in vitro binding experiments of Cry1Ab and Cry1Ac protoxin, performed with CAD protein from P. gossypiella and M. sexta larvae (21, 22), with bioassays performed in the cell line CF203 and 10 resistant strains of Diatraea saccharalis, Helicoverpa armigera, Helicoverpa zea, and Ostrinia nubilalis, against which protoxin was more potent than activated toxin (18–20).

The new results revealing binding of the C-terminal region of Cry1Ab protoxin to ALP and APN provide evidence of the mechanism by which protoxin could exert toxicity by binding to receptors, leading to toxin oligomerization and pore formation. For protoxins to exert toxicity, it is required that the full protoxin reaches the CAD receptor located in brush border membranes before activation by midgut proteases. Thus, high-affinity binding sites of protoxins to the abundant glycosylphosphatidylinositol-anchored proteins could provide means for the binding of protoxin to brush border membranes before its activation. Fig. 7 shows a model of the mechanism of action of Cry1A protoxin, showing that interaction with APN and ALP helps the protoxin to reach the CAD receptor before activation by midgut proteases. Interaction of protoxin with CAD by means of domain II exposed loops, in the presence of midgut proteases, would induce the formation of a robust oligomer that displays pore formation activity with a single conductance and high open probability, as demonstrated previously (21).

The new results presented here show that mutations Cry1Ab-RR368–369AA in loop 2 and Cry1Ab-G439D in loop 3 of domain II reduced binding to ALP and APN of the activated toxin but not of the protoxin, indicating differences in binding sites to ALP and APN between Cry1Ab protoxin and activated toxin. The specific sites of protoxin involved in interaction with ALP and APN remain to be elucidated. In particular, it will be useful to test the hypothesis that binding occurs via domains V and VII, which resemble carbohydrate-binding modules and are structurally similar to domains II and III of the activated toxin (24). It also remains to be analyzed whether the C-terminal region binds to the ABC transporter proteins that are important proteins implicated in the toxicity of Cry1A toxins (38–40). Recent data have shown that domain II loops are the regions of Cry1A activated toxins involved in the interaction with the ABCC2 transporter (41).

In contrast to the results with ALP and APN, binding to CAD (CR12) by protoxin and activated toxin was greatly reduced for all three of the Cry1Ab mutants tested (Cry1Ab-RR368–369AA and Cry1Ab-F371A in loop 2 and Cry1Ab-G439D in loop 3). These findings suggest that loops 2 and 3 of domain II are important for binding of both Cry1Ab protoxin and activated toxin to CAD in M. sexta. Thus, similar sites of domain II of both molecules participate in CAD interaction.

In other pore-forming toxins, it has been reported that they bind to their receptors as protoxins and that the propeptides, when they are proteolyzed, may display additional functions, such as chaperones that help to keep the protein in question soluble under certain conditions and assist with its secretion or oligomerization (42). For example, the C-terminal propeptide of aerolysin from Aeromonas hydrophila assists in oligomerization and pore formation (43). Also, the Clostridium septicum pore-forming a-toxin is secreted as a protoxin, and its propeptide function as a chaperone (44). Here we found that the C-terminal region of Cry1Ab protoxin binds ALP and APN. An additional important implication of this finding is that this region may influence specificity and toxicity. If so, then, similar to achievements observed previously with activated toxins, where it has been shown that domain swapping and site-directed mutagenesis as well as evolution of toxins resulted in improved toxins (45–47), the engineering of the C-terminal region could potentially generate novel Cry proteins that could be more potent against specific target insects or may help to counter insect resistance.

Materials and methods

Purification of Cry1Ab WT and mutant proteins

The Bt 407 strain (48) transformed with pHT315-cry1Ab (49), pHT315-cry1AbRR368–369AA, pHT315-cry1AbF371A, or pHT315-cry1AbG439D (16, 30) plasmids was grown for 3 days at 30 °C until complete sporulation in SP medium (0.8% nutrient broth, 1 mM MgSO4·7H2O, 13 mM KCl, and 10 mM MnCl2·4H2O (pH 7.0) supplemented with 2 ml/liter of sterile solution of 131 mM FeSO4·7H2O in 1N H2SO4 and 1 ml/liter of...
C-terminal region of Cry1Ab protoxin binds to APN and ALP

Figure 6. ELISA binding assays of Cry1Ab and Cry1Ab-mutant proteins to the purified recombinant CAD (CR12), ALP, or APN expressed in E. coli cells. The three Cry1Ab mutants (Cry1Ab-RR368–369AA, Cry1Ab-F371A, and Cry1Ab-G439D) were affected in toxicity against M. sexta larvae. A, binding of protoxin or activated toxin molecules to the purified CAD (CR12) receptor fragment. B, binding of protoxin or activated toxin molecules to purified ALP. C, binding of protoxin or activated toxin molecules to purified APN. Each experiment was performed in duplicate with a total of three repetitions. Standard deviations are shown.
sterile 0.5 mM CaCl₂) supplemented with erythromycin at 10 μg/ml. Spores/crystals were washed three times in 300 mM NaCl and 10 mM EDTA and then three times with 1 mM phenylmethylsulfonyl fluoride (PMSF) and stored at 4 °C. The crystalline inclusions were purified by discontinuous sucrose gradients as described previously (50). Protoxins were solubilized in alkaline buffer (50 mM Na₂CO₃, 0.02% β-mercaptoethanol (pH 10.5)) for 1 h at 37 °C and centrifuged for 20 min at 12,857 x g. For activation, the pH level of the protoxin solution was lowered to 8.5 by adding 1:4 (w/v) of 1 M Tris buffer (pH 8), and 1:50 trypsin (trypsin:toxin) (L-1-tosylamido-2-phenylethyl chloromethyl ketone–treated trypsin from bovine pancreas, Sigma-Aldrich) was added for 1 h at 37 °C; after this incubation, PMSF (1 mM final concentration) was added. The trypsin-activated toxins were loaded into a HiTrap Q HP column connected to an FPLC system (ÄKTA, GE Healthcare Life Sciences). The CAD fragments CR12 (G1370-A1485) and CR7–12, APN, or ALP in 100 μl of PBST buffer containing anti-rabbit HRP-conjugated antibody (1:30,000) (Santa Cruz Biotechnology) for 1 h at 37 °C. Finally, the unbound proteins were removed by three washes with PBST (pH 8.5). The protein concentration was determined by using the Bradford assay (Bio-Rad) with BSA as the standard. The quality of the samples was analyzed by SDS-PAGE (10% acrylamide) stained with Coomassie Blue and by Western blotting using a specific anti-Cry1Ab antibody (Figs. S1 and S2).

Cloning of the C-terminal fragment

The C-terminal fragment was amplified with specific primers: ForCr-ter, 5’-TAT CTG GGA TCC TCG AAT TGA ATT TGT TCC GGC AG-3’; RevCr-ter, 5’-GAG CTC GAA TTC AAT TCC ATA AGA AGT AAT TCC-3’. The PCR product was digested with BamHI and EcoRI and cloned into pET-22b (Novagen, Madison, WI). Plasmids were DNA-sequenced in the facilities of the Instituto de Biotecnología, Universidad Nacional Autónoma de México.

Toxicity assays against M. sexta larvae

Bioassays were performed with neonate larvae using five concentrations of Cry1Ab protoxin, activated toxin, or C-terminal fragment solutions that were poured onto the surface of the diet. We used 24-well polystyrene plates and one plate per dose in triplicate. Mortality was analyzed after 7 days, and the 50% lethal concentration (LC₅₀) was calculated with Probit LeOra software. Negative controls without protein addition were included.

Preparation of BBMVs from M. sexta larvae

The M. sexta colony was maintained on an artificial diet under laboratory conditions at 28 ± 2 °C and 65% ± 5% relative humidity under a 12:12 (light-dark) photoperiod. The midgut tissue was dissected from third-instar larvae. The BBMVs were prepared as described previously (51) and stored at −70 °C. The BBMV protein concentrations were determined with the Lowry DC protein assay (Bio-Rad) using BSA as the standard. The enrichment of APN (5-fold) and ALP (4-fold) activities in the BBMVs in relation to the homogenate was analyzed as reported previously (16).

Expression and purification of recombinant Cry receptors and the C-terminal fragment

CAD (CR12 and CR7–12), ALP, and APN from M. sexta larvae were cloned in pET-22b and expressed in E. coli cells (52–54). The CAD fragments CR12 (G1370–A1485) and CR7–12 (M810–A1485) were expressed in E. coli ER2566. ALP, APN, and the C-terminal fragment were expressed in E. coli BL21 (DE3) (Invitrogen). Expression was induced with 1 mM isopropyl 1-thio-β-D-galactopyranoside, and inclusion bodies were solubilized with 8 M urea as reported previously (52–54). The recombinant proteins were purified through a nickel affinity column that bound the recombinant proteins through the His tag peptide added in the pET-22b cloning vector. Proteins were eluted with 250 mM imidazole in PBS as described previously (29, 52–54). The quality of the samples was analyzed by SDS-PAGE (10% acrylamide) stained with Coomassie Blue and by Western blotting using a specific anti-C terminus antibody (Figs. S1 and S2).

ELISA binding assays

ELISA plates were coated with 0.5 μg of M. sexta CAD (CR12 or CR7–12), APN, or ALP in 100 μl of PBS/well overnight at 4 °C or with 1 μg of BBMVs. Plates were washed three times with PBS, blocked with 200 μl/well of PBS-M (PBS and 2% skim milk) for 2 h at 37 °C and washed three times with PBS. Different concentrations of protoxin or activated toxins of WT or mutants or the C-terminal fragment from Cry1Ab were added to a total 100-μl volume of PBST (PBS and 0.1% Tween 20) for 1 h at 37 °C. The unbound proteins were removed by three washes with PBST and three washes with PBS. The bound proteins were detected using 100 μl of PBST buffer containing anti-Cry1Ab (1:20,000) polyclonal antibody for 1 h at 37 °C or anti-C-terminus (1:30,000) polyclonal antibody. After three washes with PBST and three washes with PBS, we added 100 μl of PBST containing anti-rabbit HRP-conjugated antibody (1:20,000) (Santa Cruz Biotechnology) for 1 h at 37 °C. Finally, three washes with PBST were done, and proteins were incubated with 100 μl/well of substrate mixture (2 mM O-phenylenediamine (Sigma) and 0.05% H₂O₂ in 0.1 M phosphate buffer (pH 5.0)). The reaction was stopped with 60 μl of 5 M HCl and measured at A₄₉₀nm using an ELISA plate reader. Each experiment was performed in duplicate with three repetitions. Data were analyzed with the SigmaPlot program (version 12.0) and adjusted with Scatchard plot analysis.

The anti-C-terminus polyclonal antibody was raised in a New Zealand White rabbits after subcutaneous immunization with purified C-terminal fragment. The rabbit was boosted three times with 1 mg of the C-terminal fragment mixed with incomplete Freund’s adjuvant at 15-day intervals. Blood serum
**C-terminal region of Cry1Ab protoxin binds to APN and ALP**

Figure 7. Proposed mechanism of action of Cry protoxins from Bt. 1, the parasporal crystals are solubilized into protoxin. 2, the C-terminal region of protoxin binds with highly abundant APN and ALP receptors. 3, the protoxin binds to the CAD receptor by the loops of domain II. 4, proteases activate the protoxin, inducing oligomer formation. 5, the oligomer inserts into the membrane, forming a pore that kills the cell. The interaction with APN and ALP with the C-terminal region helps the protoxin to reach the CAD receptor before proteolytic activation, and the interaction of protoxin with CAD in the presence of midgut proteases induces the formation of a robust oligomer that displays high pore formation activity with single conductance and a high open probability, as demonstrated previously (18).

was obtained. Specificity and sensitivity were determined in a ligand blot assay of the C-terminal fragment spotted on nitrocellulose strips and analyzed with different concentrations of the polyclonal anti-C-terminus antibody (from 1:10,000 to 1:50,000 dilutions) and the secondary goat anti-rabbit HRP antibody (1:30,000 dilution). All procedures involving animals were conducted according to the ethical guidelines of the Instituto de Biotecnología, Universidad Nacional Autónoma de México.

**Biosensor (SPR) analysis of C-terminal binding to Cry1Ab-receptors**

The SENSIT-Q instrument was used to perform SPR measurements. Running buffer (HBS buffer (pH 7.4) containing 0.1 M HEPES, 1.5 M NaCl, and 0.005% (v/v) Tween 20) was freshly prepared, filtered (pore size of 0.22 μm), and degassed. The C-terminal fragment of Cry1Ab was immobilized onto a COOH functionalized sensor chip (ICX Nomadics) by conventional amine coupling at densities of less than 1500 response units (RU). Then 1 M ethanolamine at a flow rate of 10 μl/min for 5 min was injected to block flow cells. The analytes (CAD (CR7–12), APN, or ALP) were injected at a flow rate of 25 μl/min. Serial doubling dilutions of Cry1Ab receptors were analyzed, and the surface was regenerated with a 1-min injection of 20 mM NaOH. Injections were performed three times for each receptor protein concentration. The data were analyzed using SensiTQ Software Qdat version B.02. This software employs nonlinear regression and the Levenberg–Marquardt algorithm to fit experimental data to a binding interaction model that defines the interaction.

**Ligand blot assay**

Serial dilutions of the recombinant CAD (CR7–12), ALP (5, 2.5, 1.25, and 0.625 μg), and APN (10, 5, and 2.5 μg) proteins were separated by 10% SDS-PAGE and transferred to a PVDF membrane. The PVDF membrane was blocked with PBS supplemented with 5% skimmed milk, and blots were incubated for 1 h at room temperature with Cry1Ab protoxin, activated toxin, or the C-terminal fragment. We used 5 nm protein in washing buffer (0.1% Tween 20 in PBS) for the ligand blot analysis with CR7–12 and 200 nm protein for the ligand blot analysis with ALP and APN. Unbound proteins were removed by washing three times in washing buffer for 15 min. Bound toxin and protoxin were identified with anti-Cry1Ab polyclonal antibody (1:20,000 dilution) and bound C-terminal fragment with anti-C-terminus polyclonal antibody (1:20,000 dilution) for 1 h at room temperature. After washing, the membrane was incubated with the secondary goat anti-rabbit HRP antibody (1:20,000 dilution) for 1 h at room temperature. After washing the excess of unbound secondary antibody, proteins were visualized with Super Signal chemiluminescence substrate (Pierce).

**Pulldown assays**

BBMVs from *M. sexta* were solubilized for 2 h at 4 °C in 20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, and 1 mM PMSF containing 1% CHAPS (v/v). Undissolved material was removed by centrifugation at 100,000 × *g* for 1 h at 4 °C. We used 100 μg of purified Cry1Ab activated toxin, protoxin, or C-terminus that was incubated with 200 μl of CNBr-agarose (GE Healthcare) in 0.1 M sodium phosphate buffer (pH 7.5) at 4 °C overnight. The noncoupled proteins were removed by centrifugation. The unreacted CNBr groups were blocked with 0.1 M Tris–HCl (pH 8) at room temperature for 2 h. The resin was washed five times with 500 μl of PBS. The CNBr beads coupled to toxin, activated toxin, or the C-terminal fragment were incubated with 200 μg of solubilized BBMV proteins in 500 μl for 1 h at 4 °C; the unbound BBMV proteins were removed by centrifugation at 18,400 × *g* for 10 min at 4 °C. The coupled CNBr-agarose beads containing the bound proteins from BBMV were washed five times with 500 μl of PBS supplemented with 1 mM NaCl, followed by five washes with 500 μl of PBS to remove unbound proteins. The proteins that remained bound to the CNBr protoxin−, activated toxin−, or C-terminal−agarose beads were dissociated after 5 min at 100 °C in 50 μl of loading buffer (100 mM
TrisCl, 200 mM DTT, 4% SDS (w/v), 0.2% bromphenol blue (w/v), and 20% glycerol (v/v) (pH 6.8). As a negative control, the activated CNBr-agarose was incubated without Cry1Ab protein, blocked as described above, and incubated with solubilized BBMV. The pulled down proteins were separated in 10% SDS-PAGE and transferred to PVDF membranes that were used in Western blotting assays using anti-CAD, anti-ALP, and anti-APN polyclonal antibodies as described below.

Western blotting assays

The anti-Cry1Ab, anti-CAD, anti-ALP, and anti-APN polyclonal antibodies were raised previously in our laboratory. The anti-C-terminal antibody was raised for this work as reported above. For Western blot assays, the PVDF membranes were probed with a 1:10,000, anti-Cry1Ab 1:20,000, and anti-C-terminus 1:20,000 dilutions) and for 1 h with goat anti-rabbit HPR secondary antibody (Santa Cruz Biotechnology) (1:20,000 dilution) and finally with the anti-CAD, anti-ALP, and anti-APN polyclonal antibody (anti-CAD 1:20,000, anti-ALP and anti-APN 1:20,000, anti-Cry1Ab 1:20,000, and anti-C-terminus 1:20,000 dilutions) and for 1 h with goat anti-rabbit HPR secondary antibody (Santa Cruz Biotechnology) (1:20,000 dilution) and finally visualized by incubation with Super Signal chemiluminescence substrate (Pierce) according to the manufacturer’s instructions.

Author contributions—A. P.-C., B. E. T., A. B. M. S., and I. G. formal analysis; A. P.-C., R. G., A. B. M. S., and I. G. investigation; A. P.-C., R. G., J. S., M. S., and I. G. methodology; J. S. supervision; B. E. T., A. B., M. S., and I. G. writing-review and editing; A. B. and I. G. funding acquisition; I. G. conceptualization; I. G. writing-original draft.

Acknowledgments—We thank Lizbeth Cabrera for technical assistance.

References

1. James, C. (2010) Global status of commercialized biotech/GM crops in 2017: Biotech crop adoption surges as economic benefits accumulate in 22 years. ISAAA Brief No. 53, ISAAA, Ithaca, NY

2. Sanahuja, G., Banakar, R., Twyman, R. M., Capell, T., and Christou, P. (2011) Bacillus thuringiensis: a century of research, development and commercial application. Plant Biotechnol. J. 9, 283–300 CrossRef Medline

3. Mendelsohn, M., Kough, J., Vaituzis, Z., and Matthews, K. (2003) Are Bt crops safe? Nat. Biotechnol. 21, 1003–1009 CrossRef Medline

4. Nicolía, A., Manzo, A., Veronesi, F., and Rosellini, D. (2014) An overview of the last 10 years of genetically engineered crop safety research. Crit. Rev. Biotechnol. 34, 77–88 CrossRef Medline

5. Comas, C., Lumbierres, B., Pons, X., and Albajes, R. (2014) No effects of Bacillus thuringiensis maize on nontarget organisms in the field in southern Europe: a meta-analysis of 26 arthropod taxa. Transgenic Res. 23, 135–143 CrossRef Medline

6. Downes, S., Mahon, R. J., Rossiter, L., Kauter, G., Leven, T., Fitt, G., and Baker, G. (2010) Adaptive management of pest resistance by Helicoverpa species (Noctuidae) in Australia to the Cry2Ab Bt toxin in Bollgard II(R) cotton. Evolutionary Applications 3, 574–584 CrossRef Medline

7. Hutchison, W. D., Burkhour, E. C., Mitchell, P. D., Moon, R. D., Leslie, T. W., Fleischer, S. J., Abrahamsson, M., Hamilton, K. L., Steffey, K. L., Gray, M. E., Hellmich, R. L., Kaster, L. V., Hunt, T. E., Wright, R. J., Pecnovsny, K., et al. (2010) Areawide suppression of European corn borer with Bt maize reaps savings to non-Bt maize growers. Science 330, 222–225 CrossRef Medline

8. Tabashnik, B. E., Sirson, M. S., Ellsworth, P. C., Dennehy, T. J., Antilla, L., Lissner, L., Whitlow, M., Staten, R. T., Fabrick, J. A., Unnithan, G. C., Yelich, A. J., Ellers-Kirk, C., Harpold, V. S., Li, X., and Carriere, Y. (2010) Suppressing resistance to Bt cotton with sterile insect releases. Nat. Biotechnol. 28, 1304–1307 CrossRef Medline

9. Lu, Y., Wu, K., Jiang, Y., Guo, Y., and Desneux, N. (2012) Widespread adoption of Bt cotton and insecticide decrease promotes biocontrol services. Nature 487, 362–365 CrossRef Medline

10. Wan, P., Wu, K., Huang, M., Yu, D., and Wu, J. (2008) Population dynamics of Spodoptera littura (Lepidoptera: Noctuidae) on Bt cotton in the Yangtze River Valley of China. Environ. Entomol. 37, 1043–1048 CrossRef Medline

11. Dively, G. P., Venugopal, P. D., Bean, D., Whalen, J., Holmstrom, K., Kuhar, T. P., Doughty, H. B., Patton, T., Cissel, W., and Hutchison, W. D. (2018) Regional pest suppression associated with widespread Bt maize adoption benefits vegetable growers. Proc. Natl. Acad. Sci. U.S.A. 115, 3320–3325 CrossRef Medline

12. Wu, Y. D. (2014) Detection and mechanisms of resistance evolved in insects to Cry toxins from Bacillus thuringiensis. In: Advances in Insect Physiology (Dhadialla, T. S., and Gill, S. S., eds), Vol. 47, pp. 297–342, Elsevier BV, Amsterdam CrossRef Medline

13. Tabashnik, B. E., and Carrière, Y. (2017) Surge in insect resistance to transgenic crops and prospects for sustainability. Nat. Biotechnol. 35, 926–935 CrossRef Medline

14. Pardo-López, L., Soberón, M., and Bravo, A. (2013) Bacillus thuringiensis insecticidal three-domain Cry toxins: mode of action, insect resistance and consequences for crop protection. FEMS Microbiol. Rev. 37, 3–22 CrossRef Medline

15. Adang, M. J., Crikmcore, N., and Jurat-Fuentes, J. L. (2014) Diversity of Bacillus thuringiensis crystal toxins and mechanism of action. In: Advances in Insect Physiology (Dhadialla, T. S., and Gill, S. S., eds), Vol. 47, pp. 39–87, Elsevier BV, Amsterdam CrossRef Medline

16. Arenas, I., Bravo, A., Soberón, M., and Gómez, I. (2010) Role of alkaline phosphatase from Manduca sexta in the mechanism of action of Bacillus thuringiensis Cry1Ab toxin. J. Biol. Chem. 285, 12497–12503 CrossRef Medline

17. Zhang, X., Candas, M., Grikoo, N. B., Tasssieg, R., and Bulla, L. A., Jr. (2006) A mechanism of cell death involving an adenyly cyclase/PKA signaling pathway is induced by the Cry1Ab toxin of Bacillus thuringiensis. Proc. Natl. Acad. Sci. U.S.A. 103, 9897–9902 CrossRef Medline

18. Tabashnik, B. E., Zhang, M., Fabrick, J. A., Wu, Y., Gao, M., Huang, F., Wei, J., Zhang, J., Yelich, A., Unnithan, G. C., Bravo, A., Soberón, M., Carrière, Y., and Li, X. (2015) Dual mode of action of Bt proteins: protoxin efficacy against resistant insects. Sci. Rep. 5, 15107 CrossRef Medline

19. Siqueira, H. A., Nickerson, K. W., Moellenbeck, D., and Siegfried, B. D. (2004) Activity of gut proteases from Cry1Ab-selected colonies of the European corn borer, Ostrinia nubilalis (Lepidoptera: Crambidae). Pest Management Science 60, 1189–1196 CrossRef Medline

20. Anilkumar, K. J., Rodrigo-Simón, A., Ferré, J., Pusztai-Carey, M., Sivasupramaniam, S., and Moar, W. J. (2008) Production and characterization of Bacillus thuringiensis Cry1Ac-resistant cotton bollworm Helicoverpa zea (Boddie). Applied Environ. Microbiol. 74, 462–469 CrossRef Medline

21. Gómez, I., Sánchez, J., Muñoz-Garay, C., Matus, V., Gill, S. S., Soberón, M., and Bravo, A. (2014) Bacillus thuringiensis Cry1A toxins are versatile proteins with multiple modes of action: two distinct pre-pores are involved in toxicity. Biochim. J. 459, 383–396 CrossRef Medline

22. Fabrick, J. A., and Tabashnik, B. E. (2007) Binding of Bacillus thuringiensis toxin Cry1Ac to multiple sites of cadherin in pink bollworm. Insect Biochem. Mol. Biol. 37, 97–106 CrossRef Medline

23. Li, X., Zhao, F., Qiu, X., Ren, X., Mo, X., Ding, X., Xia, L., and Sun, Y. J. (2018) The full-length Cry1Ac protoxin without proteolytic activation exhibits toxicity against insect cell line CF-203. J. Invertebr. Pathol. 152, 25–29 CrossRef Medline

24. Evdokimov, A. G., Moshiri, F., Sturman, E. J., Rydel, T. J., Zheng, M., Seale, J. W., and Franklin, S. (2014) Structure of the full-length insecticidal three-domain Cry toxins: mode of action, insect resistance and consequences for crop protection. Proc. Natl. Acad. Sci. U.S.A. 115, 926–935 CrossRef Medline

25. Rajamohan, F., Alcantara, E., Lee, M. K., Chen, X. J., Curtiss, A., and Dean, D. H. (1995) Single amino acid changes in domain II of Bacillus thuringiensis C-terminal region of Cry1Ab protoxin binds to APN and ALP.
C-terminal region of Cry1Ab protoxin binds to APN and ALP

Cry1Ab 8-endotoxin affect irreversible binding to Manduca sexta midgut membrane vesicles. *J. Bacteriol.* **177**, 2276–2282 CrossRef Medline

Rajamohan, F., Cotrill, J. A., Gould, F., and Dean, D. H. (1996) Role of domain II, loop 2 residues of *Bacillus thuringiensis* Cry1Ab 8-endotoxin in reversible and irreversible binding to *Manduca sexta* and *Heliothis virescens*. *J. Biol. Chem.* **271**, 2390–2396 CrossRef Medline

Jenkins, J. L., and Dean, D. H. (2000) Exploring the mechanism of action of insecticidal proteins by genetic engineering methods. In: *Genetic Engineering (Principles and Methods)* (Setlow, J. K., ed), Vol. 22, pp. 33–54, Springer, Boston, MA

Lee, M. K., Rajamohan, F., Jenkins, J. L., Curtiss, A. S., and Dean, D. H. (2000) Role of two arginine residues in domain II, loop 2 of Cry1Ab and Cry1Ac *Bacillus thuringiensis* 8-endotoxin in toxicity and binding to *Manduca sexta* and *Lymnaea dispar* aminopeptidase N. *N. Mol. Microbiol.* **38**, 289–298 CrossRef Medline

Pacheco, S., Gómez, I., Gill, S. S., Bravo, A., and Soberón, M. (2009) Enhancement of insecticidal activity of *Bacillus thuringiensis* Cry1A toxins by fragments of a toxin-binding cadherin correlates with oligomer formation. *Peptides* **30**, 583–588 CrossRef Medline

Rodríguez-Almazán, C., Zavala, L. E., Muñoz-Garay, C., Jiménez-Juárez, N., Pacheco, S., Masson, L., Soberón, M., and Bravo, A. (2009) Dominant negative mutants of *Bacillus thuringiensis* Cry1Ab toxin function as anti-toxins: demonstration of the role of oligomerization in toxicity. *PLoS ONE* **4**, e5545 CrossRef Medline

Sneddon, D. P., and Ellar, D. J. (1996) Mutagenesis of three surface-exposed loops of a *Bacillus thuringiensis* insecticidal toxin reveals residues important for toxicity, receptor recognition and possibly membrane insertion. *Microbiology* **142**, 1617–1624 CrossRef Medline

Chen, J., Hua, G., Jurat-Fuentes, J. L., Abdullah, M. A., and Adang, M. J. (2007) Synergism of *Bacillus thuringiensis* toxins by a fragment of a toxin-binding cadherin. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 13901–13906 CrossRef Medline

Gómez, I., Dean, D. H., Bravo, A., and Soberón, M. (2003) Molecular basis for *Bacillus thuringiensis* Cry1Ab toxin specificity: two structural determinants in the *Manduca sexta* Br-R1 receptor interact with loops α-8 and 2 in domain II of Cry1Ab toxin. *Biochemistry* **42**, 10482–10489 CrossRef Medline

Xie, R., Zhuang, M., Ross, L. S., Gomez, I., Oltean, D. I., Bravo, A., Soberón, M., and Gill, S. S. (2005) Single amino acid mutations in the cadherin receptor from *Heliotis virescens* affect its toxin binding ability to Cry1A toxins. *J. Biol. Chem.* **280**, 8416–8425 CrossRef Medline

de Maagd, R. A., Kwa, M. S., van der Klei, H., Yamamoto, T., Schipper, B., Vlak, J. M., Stiekema, W. J., and Bosch, D. (1996) Domain III substitution in *Bacillus thuringiensis* 8-endotoxin Cry1Ab results in superior toxicity for *Spodoptera exigua* and altered membrane protein recognition. *Appl. Environ. Microbiol.* **62**, 1537–1543 Medline

Bravo, A., Gómez, I., Porta, H., García-Gómez, B. I., Rodriguez-Almazán, C., Pardo, L., and Soberón, M. (2013) Evolution of *Bacillus thuringiensis* Cry toxins insecticidal activity. *Microbial Biotechnology* **6**, 17–26 CrossRef Medline

Badran, A. H., Guzov, V. M., Hui, Q., Kemp, M. M., Vishwanath, P., Kain, W., Nance, A. M., Evedkimon, A., Moshiri, F., Turner, K. H., Wang, P., Malvar, T., and Liu, D. R. (2016) Continuous evolution of *Bacillus thuringiensis* toxins overcomes insect resistance. *Nature* **533**, 58–63 CrossRef Medline

Lereclus, D., Agaisse, H., Gominet, M., and Chaufoux, J. (1995) Overproduction of encapsulated insecticidal crystal proteins in a *Bacillus thuringiensis* spoOA mutant. *Biotechnology* **13**, 67–71 Medline

Meza, R., Nuñez-Valdez, M. E., Sanchez, J., and Bravo, A. (1996) Isolation of *Cry*1A protein mutants of *Bacillus thuringiensis* by a highly efficient PCR site-directed mutagenesis system. *FEMS Microbiol. Lett.* **145**, 333–339 CrossRef Medline

Thomas, W. E., and Ellar, D. J. (1983) *Bacillus thuringiensis* var. *israelensis* crystal 8-endotoxin: effects on insect and mammalian cells in vitro and in vivo. *J. Cell Sci.* **60**, 181–197 Medline

Woltersbergen, M. G. (1993) Preparation and partial characterization of amino acid transporting brush border membrane vesicles from the larval midgut of the gypsy moth (*Lymantria dispar*). *Archives Insect Biochem. Physiol.* **24**, 139–147 CrossRef Medline

Flores-Escober, B., Rodriguez-Magadan, H., Bravo, A., Soberón, M., and Gómez, I. (2013) Differential role of *Manduca sexta* aminopeptidase-N and alkaline phosphatase in the mode of action of *Cry*1Aa, *Cry*1Ab, and *Cry*1Ac toxins from *Bacillus thuringiensis*. *Appl. Environ. Microbiol.* **79**, 4543–4550 CrossRef Medline

Torres-Quintero, M. C., Gómez, I., Pacheco, S., Sánchez, J., Flores, H., Osuna, J., Mendoza, G., Soberón, M., and Bravo, A. (2018) Engineering *Bacillus thuringiensis* Cry1Aa toxin specificity from dipteran to lepidopteran toxicity. *Sci. Rep.* **8**, 4989 CrossRef Medline

Jiménez-Juárez, N., Muñoz-Garay, C., Gómez, I., Saab-Rincon, G., Damián-Almazo, J. Y., Gill, S. S., Soberón, M., and Bravo, A. (2007) *Bacillus thuringiensis* Cry1Ab mutants affecting oligomer formation are non-toxic to *Manduca sexta* larvae. *J. Biol. Chem.* **282**, 21222–21229 CrossRef Medline